Shanghai Junshi Biosciences Co. Ltd (SHJBF PINK) stock market data APIs
$3.0614
0(0%)
as of January 2, 2026
Try our APIs with
free plan!
Shanghai Junshi Biosciences Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Prev. Close
3.0614
Open
3.0614
High
3.0614
Low
3.0614
52 wk Range
1.3-4.2285
Market Cap
4 229 M
Shares Outstanding
260 M
Revenue
2 483 M
EPS
-0.0249
Beta
0.913
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shanghai Junshi Biosciences Co. Ltd data using free add-ons & libraries
Get Shanghai Junshi Biosciences Co. Ltd Fundamental Data
Shanghai Junshi Biosciences Co. Ltd Fundamental data includes:
- Net Revenue: 2 483 M
- EBITDA: -760 440 640
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: NaN
Get Shanghai Junshi Biosciences Co. Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shanghai Junshi Biosciences Co. Ltd News
New
Shanghai Junshi Biosciences (SEHK:1877): Revisiting Valuation After a Volatile Share Price Rebound
Shanghai Junshi Biosciences (SEHK:1877) has quietly turned into one of Hong Kong’s more interesting biotech comeback stories, with the share price up sharply this year despite heavy volatility over ...
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Junshi Biosciences Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R...
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
Junshi Biosciences SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical compan...
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
Junshi Biosciences SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical compan...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
